Many scientists believe that a major factor in the failure to establish or maintain a pregnancy is when the cells in the embryo contain the wrong number of chromosomes, a condition termed aneuploidy.
24sure is the first array technology that enables scientists to screen for aneuploidy and confirm that the correct number of chromosomes are present in an egg or embryo. Many researchers believe this should increase the likelihood of an embryo transferred during IVF treatment resulting in a successful pregnancy.
24sure is unique because it makes thousands of independent measurements of the chromosomes at a molecular level. This is believed to be more accurate than previous techniques which relied on visual inspection of the embryo or of a limited number of chromosomes under a microscope.
24sure is automated and objective which ensures a high degree of confidence may be placed in the results. Screening with 24sure may be completed in as little as 12 hours and does not impact the tight schedules of a fresh IVF cycle.
24sure may be used to screen for aneuploidy in any of the cells that are available within an IVF cycle including first and second polar bodies, blastomere biopsies and biopsies of the trophectoderm.
The impact of 24sure on live birth rate is the subject of a number of ongoing studies.
For more information on 24sure please download the product brochure or see www.24suretest.com.
